-+ 0.00%
-+ 0.00%
-+ 0.00%

KURA ONCOLOGY REPORTS DARLIFARNIB PLUS CABOZANTINIB DEMONSTRATES ROBUST ACTIVITY IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA PREVIOUSLY TREATED WITH CABOZANTINIB

Reuters·04/17/2026 10:00:00

Please log in to view news